Exposing Lee Zeldin’s Record on Healthcare

David Posnett — Thu, 05 Mar 2020 17:15:21 +0000

Remember the Graham Cassidy bill?

Representative Lee Zeldin (R-NY1) is a master at telling half-truths. He goes to great lengths to tell his constituents that he supports healthcare coverage for people with pre-existing conditions and lowering prescription drug prices, but his voting record says differently. Zeldin voted against coverage for pre-existing conditions, and just recently shot down a bill for prescription drug coverage reform and prescription drug coverage reform. He even has the audacity to take credit for programs he voted against. A quick look at his record, however, is quite revealing.

Lee Zeldin voted to repeal the Affordable Care Act (ACA). He has cast several such votes in his three terms in office, most recently May 2017 (and he openly urges the courts to overturn the ACA now). The federal requirement to provide coverage for people with pre-existing conditions comes directly from the ACA, so Zeldin’s opposition to coverage for pre-existing conditions is right there in his votes! Zeldin and Trump claim to offer ACA-replacement legislation that provides for pre-existing condition coverage, but these bills do not protect consumers, especially those with pre-existing conditions. They provide no requirement that these individuals will not be penalized in pricing and availability of coverage.

When Congress, in December 2019, passed its bill to make prescription drugs more affordable, Lee Zeldin voted against the bill (HR-3). His position on this critical issue is again demonstrated by his vote. The only effective way to control the cost of prescription drugs is to let Medicare, the largest consumer, negotiate drug prices directly with the manufacturers. It’s no surprise that Zeldin continues to prohibit Medicare from negotiating because much of his campaign contributions come from drug makers and their affiliates. This isn’t me saying this, it’s right there in his campaign finance reports that he is legally obligated to file with the Federal Election Commission. Given Zeldin’s benefactors, it’s no wonder he opposes true prescription price reforms.

Zeldin takes credit for funding medical research at Stony Brook. His most recent February “newsletter” stated that he secured $3 million of new NIH grants to Stony Brook for medical research, and he cites a bi-partisan letter he signed requesting a budget increase specifically for NIH research. What Zeldin does not tell you is that when the actual budget came to a vote on July 25, 2019, he voted against it. His own voting record proves that Zeldin did not vote to increase NIH appropriations or increased funding for Stony Brook.

But Zeldin’s biggest deception of all is that he is has listened and knows what his constituents need for their healthcare. Again, the facts belie that. Zeldin’s last public town hall was in April 2017, before his vote to repeal the ACA. He has not held one since then. He has no idea what his constituents want or need!

Town halls are meant to be open to ALL constituents who want to attend. There should be no prescreening of questions or questioners (to exclude critics) or else it is not really a true town hall. I know this from first-hand experience.

I have held five open town halls since last September and I will hold five more before the end of June. I take questions from Democrats, Republicans – whoever attends and wants to ask a question. As a matter of fact, I take each and every question asked of me and I give truthful fact-based answers. There is no pre-screening and no spin at my town halls.

People on Long Island deserve a representative who will listen to them when they speak out about healthcare. I want to see universal healthcare for everyone – and I believe we can do it with the ACA supercharged with a public option. We need to allow Medicare to negotiate drug prices to achieve true pricing reforms. This November, we have a chance to give NY-1 a representative who will fight for us in Washington and tell us the truth here at home.

Originally published in the Village Times Herald

Curb Drug Costs: Makes Sense For All

David Posnett — Thu, 23 Jan 2020 15:31:21 +0000

By Mike Anthony, on page A10 of the Southampton Press:

http://digital.olivesoftware.com/Olive/ODN/SouthamptonEast/

Makes Sense For All

Dr. David Posnett’s informative letter about House of Representative bill HR3 [“Choosing Sides,” Letters, January 9], see prior post herein, details key elements of Congress’s promise to establish a consumer- and patient-friendly drug price negotiation system. Dr. Posnett aptly captures the gist of the matter in several paragraphs.

My prime takeaway: If the Veterans Administration can negotiate drug prices, why not the Centers for Medicare and Medicaid Services? High-quality and lower-cost drugs makes sense for all of us.

As Dr. Posnett points out, Congressman Lee Zeldin repeats the canard that “these policies would siphon $1 trillion from biopharmaceutical innovators over the next 10 years.” A cynic might ask: Why don’t the drug companies use some of their robust advertising budget and redirect it to research?

The thing is, you don’t have to be a cynic to think that way. Dr. Marcia Angell reveals how drug companies have strayed from their mission in “The Truth About the Drug Companies: How They Deceive Us and What to Do About It.” Here’s an excerpt from the publisher:

“As Dr. Angell powerfully demonstrates, claims that high drug prices are necessary to fund research and development are unfounded. The truth is that drug companies funnel the bulk of their resources into the marketing of products of dubious benefit.”

Any doubt about that? Just ask Purdue Pharma, the company that pleaded guilty to criminal charges of misbranding Oxycontin by claiming that it was less addictive compared to other opioids. Purdue was fined $634 million.

Yes, drug efficacy and safety are as important as pricing — and HR3 covers that as well.

NPR reports that several overseas generic drug manufacturers abuse safety protocols. In India, about 25 percent of inspected drug manufacturing plants violated drug integrity rules; in China, 32 percent of their plants violated these rules.

To guarantee the safe manufacture of drugs, HR 3 provides $920 million to improve regulatory oversight of medical products and to protect public health. And, most important to the East End community, HR3 provides $7.5 billion in funding for states, counties, cities and towns to fight the opioid epidemic.

Contact Congressman Zeldin and ask him to reconsider his opposition to HR3: https://zeldin.house.gov/contact/offices

Mike Anthony

Westhampton

drug costs – R&R – Reachout and Rebuild

Exposing Lee Zeldin’s Record on Healthcare

Curb Drug Costs: Makes Sense For All